You are here: Home » PTI Stories » National » News
Business Standard

Single protein may help treat Parkinson's, Alzheimer's: study

Press Trust of India  |  Los Angeles 

A key cellular protein may help effectively treat neuro-degenerative diseases such as Parkinson's, Alzheimer's, Huntington's and amyotrophic lateral sclerosis (ALS), a new study has claimed.

At their root, these disorders are triggered by misbehaving proteins in the brain. The proteins misfold and accumulate in neurons, inflicting damage and eventually killing the cells.

Researchers from the Gladstone Institutes in the US used a different protein, Nrf2, to restore levels of the disease-causing proteins to a normal, healthy range, thereby preventing cell death.

The researchers tested Nrf2 in two models of Parkinson's disease: cells with mutations in the proteins LRRK2 and a-synuclein.

By activating Nrf2, they turned on several "house-cleaning" mechanisms in the cell to remove excess LRRK2 and a-synuclein.

"Nrf2 coordinates a whole programme of gene expression, but we did not know how important it was for regulating protein levels until now," said Gaia Skibinski from Gladstone.

"Overexpressing Nrf2 in cellular models of Parkinson's disease resulted in a huge effect. In fact, it protects cells against the disease better than anything else we've found," said Skibinski.

Researchers used both rat neurons and human neurons created from induced pluripotent stem cells. They then programmed the neurons to express Nrf2 and either mutant LRRK2 or a-synuclein.

Using a one-of-a-kind robotic microscope, they tagged and tracked individual neurons over time to monitor their protein levels and overall health.

They took thousands of images of the cells over the course of a week, measuring the development and demise of each one.

Researchers discovered Nrf2 worked in different ways to help remove either mutant LRRK2 or a-synuclein from the cells. For mutant LRRK2, Nrf2 drove the protein to gather into incidental clumps that can remain in cell without damaging it.

For a-synuclein, Nrf2 accelerated the breakdown and clearance of the protein, reducing its levels in the cell.

"I am very enthusiastic about this strategy for treating neurodegenerative diseases. We have tested Nrf2 in models of Huntington's disease, Parkinson's disease, and ALS, and it is the most protective thing we have ever found," said Steven Finkbeiner from Gladstone.

"Based on the magnitude and the breadth of the effect, we really want to understand Nrf2 and its role in protein regulation better," said Finkbeiner.

The scientists said that Nrf2 itself may be difficult to target with a drug because it is involved in so many cellular processes, so they are now focusing on some of its downstream effects.

They hope to identify other players in the protein regulation pathway that interact with Nrf2 to improve cell health and that may be easier to drug.

The study was published in the journal Proceedings of the National Academy of Sciences.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, December 27 2016. 14:48 IST
RECOMMENDED FOR YOU